El continuo de la EPOC y riesgo cardiovascularuna hipótesis global de la enfermedad

  1. Carlos Alberto Názara Otero 1
  2. Adolfo Baloira Villar 2
  1. 1 Servicio de Medicina Interna y Medicina de Familia, CAP-Marín EOXI Pontevedra-Salnés
  2. 2 Servicio de Neumología, CHUP Pontevedra-Salnés
Revista:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Ano de publicación: 2015

Volume: 27

Número: 3

Páxinas: 144-147

Tipo: Artigo

Outras publicacións en: Clínica e investigación en arteriosclerosis

Resumo

Chronic obstructive pulmonary disease (COPD) is a serious public health problem in our country. COPD is a treatable and preventable disease which is underdiagnosed. The EPISCAN study revealed a prevalence of 10.2% in Spain between individuals of 40-80 years, with 73% underdiagnosis. In Primary Care occupies 8.5% of all queries with a high economic impact. These patients exhibit some degree of systemic inflammation characterized by increased plasma levels of some inflammatory mediators such as IL-1, IL-6, IL-8, CRP and TNF, which are also related to endothelial disorders and arteriosclerosis. In the continuum of COPD, comorbidities most frequently appear are: ischemic heart disease, heart failure, stroke, hypertension, type 2 diabetes mellitus, renal failure, osteoporosis, myopathy, anxiety, depression, cognitive impairment, malnutrition, anemia and lung cancer.